Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma

Table 1

Patients’ characteristics () and their association with serum MMP9 before treatment.

Characteristic		(%)	MMP9 before treatment (ng/ml); Median (25%-75%)
Gender	Male	89 (80.9)	707.8 (502.3-1224.7)	0.651^a
	Female	21 (19.1)	683.5 (404.1-1231.8)
Age	Median (25%-75%) (years)	66 (59.8-72.3)	Spearman’s	0.410^b
Stage	I	12 (10.9)	595.8 (502.6-1412.1)	0.982^a
	II	22 (20.0)	729.0 (396.8-1216.0)
	III	42 (38.2)	772.3 (452.6-1277.5)
	IV	27 (24.5)	698.5 (548.9-1207.2)
	Peritoneal	7 (6.4)	757.4 (632.5-1511.6)
Histological type	Epithelioid	81 (73.6)	757.4 (497.6-1213.2)	0.830^a
	Biphasic	15 (13.6)	683.5 (393.3-1408.9)
	Sarcomatoid	11 (810.0)	641.3 (483.4-1178.1)
	Not characterized	3 (2.7)	705.7 (698.5-705.7)
ECOG performance status	0	13 (11.8)	466.7 (383.2-842.5)	0.010^a
	1	56 (50.9)	682.0 (431.5-1088.4)
	2	41 (37.3)	1026.5 (579.9-1443.0)
CRP	Median (25%-75%) (mg/l)	17.5 (6.3-54.3) [6]	Spearman’s	0.498^b
LDH	Median (25%-75%) (μkat/l)	2.6 (2.2-2.9) [6]	Spearman’s	0.505^b
Asbestos exposure	Not exposed	24 (21.8)	644.1 (502.6-1238.1)	0.625^a
	Exposed	86 (78.2)	749.1 (497.1-1216.0)
Smoking	Nonsmokers	61 (56.0) [1]	707.8 (406.6-1293.5)	0.732^a
	Smokers	48 (44.0)	687.7 (558.0-1199.9)
Pain	No	50 (45.9) [1]	641.3 (497.1-1243.9)	0.349^a
	Yes	59 (54.1)	800.2 (546.1-1242.3)
Weight loss	No	32 (29.6) [2]	868.9 (567.9-1175.4)	0.699^a
	Yes	76 (70.4)	682.0 (485.9-1357.7)

Numbers in [] denote missing data. ^aCalculated using the Mann-Whitney or Kruskal-Wallis test. ^bCalculated using Spearman’s rho. CRP: C-reactive protein; ECOG: Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase.